>>> Fed's Bullard (dove, non voter): GDP growth likely to grow in excess of 3% i

Fed's Bullard (dove, non voter): GDP growth likely to grow in excess of 3% in Q2, Q3, and Q4 - comments to reporters
- Notes that Fed could need to adjust its late Q1 2015 interest rate views in light of the lower unemployment rate 
- if unemployment drops below 6% this year, it could trigger policy adjustment discussions 
- ending reinvestment of securities can be seen as 'mild tightening', and could be useful before increasing rates

>>> Profire Energy up 20% on no news, we are looking around for a catalyst (5.0

Profire Energy up 20% on no news, we are looking around for a catalyst

PFIE is primarily a supplier of burner management systems (BMS) for the oil & gas industry. PFIE's proprietary BMS is a high-tech thermostat that monitors and manages the burner flames that are widely used in the production and transportation of oil & natural gas. Current methods to make sure burners are at the correct temp or haven't gone out are manual, inefficient, and often dangerous. PFIE's BMS electronically monitors the flames and reignites them as needed, which is a big improvement over the current manual process, and can thus can help E&P customers cut costs, improve efficiency, and reduce injuries and fatalities.

{PFIE US Equity DES <GO>}

{PFIE US Equity IGPO 5 <GO>}

>>> Achillion (ACHN) +40% : Feuerstein suggesting that ACHN may be next takeove

Achillion Pharmaceuticals TheStreet.com's Feurstein: Achillion has a pipeline of hepatitis C drugs, the most valuable, perhaps, is ACH-3422, a nucleotide NS5B polyermase inhibitor

With Merck gobbling up Idenix Pharmaceuticals, the hepatitis C takeout speculation shifts to Achillion Pharmaceuticals. Using the Idenix premium, an acquisition of Achillion would be considerably cheaper -- less than $1 billion at Friday's closing stock price. 

Like Idenix, Achillion has a pipeline of hepatitis C drugs. The most valuable, perhaps, is ACH-3422, a nucleotide NS5B polyermase inhibitor. The conventional thinking is that so-called "nucs" are the linchpin of hepatitis C combination therapy. Gilead Sciences' (GILD) Sovaldi is a nuc and will likely generate $9-10 billion in sales this year. Idenix is developing a nuc, which is probably why Merck acquired the company.